Related Experiment Video
Updated: May 7, 2026
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Bilirubin neurotoxicity in preterm infants: risk and prevention
Vinod K Bhutani1, Ronald J Wong
1Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Lucile Packard Children's Hospital, Stanford, California, USA.
Insights
Effective phototherapy has drastically reduced kernicterus in preterm infants. However, predicting bilirubin neurotoxicity risk in premature babies remains challenging, requiring refined predictive tools beyond current clinical measures.
Area of Science:
- Neonatal Medicine
- Pediatric Neurology
- Biochemistry
Background:
- Hemolytic conditions in preterm neonates, such as Rhesus (Rh) disease, pose risks of mortality and long-term neurological damage from bilirubin neurotoxicity.
- Advances in Rh immunoprophylaxis, perinatal-neonatal care, and phototherapy have significantly decreased kernicterus incidence in many regions.
- Historically, kernicterus rates were high in extremely preterm infants without modern interventions, with rates varying by gestational age.
Purpose of the Study:
- To review the historical and current landscape of bilirubin neurotoxicity in preterm neonates.
- To evaluate the effectiveness of phototherapy in managing hyperbilirubinemia and preventing kernicterus.
- To discuss the ongoing challenges in predicting bilirubin neurotoxicity risk in premature infants beyond traditional markers.
Main Methods:
- Review of historical data on kernicterus incidence in preterm infants based on gestational age.
- Analysis of the impact of phototherapy on hyperbilirubinemia and the reduction of exchange transfusions.
- Discussion of various clinical and biochemical markers for predicting bilirubin neurotoxicity, including total bilirubin, unbound bilirubin, and albumin binding.
Main Results:
- Phototherapy effectively prevents hyperbilirubinemia in preterm infants, even with hemolysis, significantly reducing the need for exchange transfusions.
- While kernicterus has been largely eliminated by phototherapy, bilirubin neurotoxicity remains a concern solely due to prematurity.
- Current objective tests and clinical observations have not yet been refined to reliably predict the individual risk of bilirubin neurotoxicity.
Conclusions:
- Effective phototherapy has transformed the management of neonatal jaundice, virtually eliminating the need for exchange transfusions.
- Predicting bilirubin neurotoxicity in preterm infants remains a significant clinical challenge, necessitating further research into refined predictive markers.
- Management strategies involve careful balancing of antioxidant exposure and avoidance of bilirubin's neurotoxic effects within established clinical thresholds.
Abstract:
Hemolytic conditions in preterm neonates, including Rhesus (Rh) disease, can lead to mortality and long-term impairments due to bilirubin neurotoxicity. Universal access to Rh immunoprophylaxis, coordinated perinatal-neonatal care, and effective phototherapy has virtually eliminated the risk of kernicterus in many countries. In the absence of jaundice due to isoimmunization and without access to phototherapy or exchange transfusion (in 1955), kernicterus was reported at 10.1%, 5.5%, and 1.2% in babies <30, 31-32, and 33-34 wks gestational age, respectively. Phototherapy initiated at 24±12 hr effectively prevented hyperbilirubinemia in infants <2,000 g even in the presence of hemolysis. This approach (in 1985) reduced exchange transfusions from 23.9% to 4.8%. Now with 3 decades of experience in implementing effective phototherapy, the need for exchange transfusions has virtually been eliminated. However, bilirubin neurotoxicity continues to be associated with prematurity alone. The ability to better predict this risk, other than birthweight and gestation, has been elusive. Objective tests such as total bilirubin, unbound or free bilirubin, albumin levels, and albumin-bilirubin binding, together with observations of concurrent hemolysis, sepsis, and rapid rate of bilirubin rise have been considered, but their individual or combined predictive utility has yet to be refined. The disruptive effects of immaturity, concurrent neonatal disease, cholestasis, use of total parenteral nutrition or drugs that alter bilirubin-binding abilities augment the clinical risk of neurotoxicity. Current management options rely on the "fine-tuning" of each infant's exposure to beneficial antioxidants and avoidance of silent neurotoxic properties of bilirubin navigated within the safe spectrum of operational thresholds demarcated by experts.
Related Concept Videos
01:19Rh Blood Group
01:25Jaundice
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:07Teratogenicity
01:24Drug Toxicity: Risk factors
01:29Hepatic Encephalopathy